On October 22, 2021, Roche announced the U.S. Food and Drug Administration (FDA) approved its VENTANA PD-L1 (SP263) Assay as a companion diagnostic for patients with non-small cell lung cancer eligible for treatment with atezolizumab.
Read Roche's announcement for more information.
Posted 10/22/2021
Understanding both the benefits to be had from offering BsAb therapy to its community and the scope of this undertaking, Vanderbilt-Ingram Cancer Center took a novel approach with its APP-led BsAb step-up dosing clinic, which won the program a 2026 ACCC Innovator Award.
